Last reviewed · How we verify
NCT07102069
Pharmacogenomic and Pharmacoepigenomic Studies of Antipsychotic Drugs in First-Episode Schizophrenia
trial in Schizophrenia in 384 participants. Completed in 14 September 2022.
14 June 2022
Quick facts
| Lead sponsor | Tianjin Anding Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 384 |
| Start date | 1 November 2017 |
| Primary completion | 14 June 2022 |
| Estimated completion | 14 September 2022 |
| Sites | 1 location across China |
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
Sponsor
Tianjin Anding Hospital
Who can join
Adults 18 to 65, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to explore the objective markers concerning schizophrenia risk and functional outcome from multiple dimensions such as multi-omics including genomics, proteomics, metabolomics, electrophysiology, imaging, psychosocial, and cognition. In summary, based on this trial, the significant outcomes may effectively improve the accuracy of early warning and recognition in patients with schizophrenia, and provide clues for the study of new drug targets.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
New genomic and proteomic biomarker discovery in cancer: revolutionizing diagnosis and prognostication.
Rajput M, Pandey M, Dixit R. · · 2026 · PMID 41593642 · DOI 10.1186/s12957-025-04185-3
Verify or expand the search:
- PubMed search for NCT07102069
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other Tianjin Anding Hospital trials
Trials by the same sponsor.
- NCT07393464 — PQQ for Cognitive and Negative Symptoms · NA · not yet recruiting
- NCT07523490 — Investigation on Suicide Risk Factors of Patients With Mood Disorders · recruiting
- NCT06812923 — TACS on High-inflammatory and Refractory Depression · NA · recruiting
- NCT07162467 — Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia. · enrolling by invitation
- NCT07359209 — Berberine Improving Cognitive Impairments in Schizophrenia · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07102069 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Anding Hospital
- Last refreshed: 3 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07102069.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing